J Am Pharm Assoc (2003). 2021 Jul-Aug;61(4):e218-e224. doi: 10.1016/j.japh.2021.01.025. Epub 2021 Mar 2.
Gabapentin is approved to treat postherpetic neuralgia and epilepsy with partial-onset seizures. The large majority of gabapentin prescribing is off label. Gabapentin may be abused for euphoria, potentiating the high from opiates, reduction of alcohol cravings, a cocaine-like high, as well as sedation or sleep. Individuals at the highest risk for abusing gabapentin include those with opioid abuse, mental illness, or previous history of prescription drug abuse. States are now taking action to track gabapentin use through prescription monitoring programs, and some states have reclassified it as a Schedule V controlled substance. This commentary summarizes gabapentin's abuse potential, identifies state-level actions regarding gabapentin monitoring, and discusses possible clinical implications and ways to enhance patient safety when prescribing gabapentin.
加巴喷丁被批准用于治疗疱疹后神经痛和部分发作性癫痫。绝大多数加巴喷丁的处方都属于超适应证用药。加巴喷丁可能被滥用于产生欣快感、增强阿片类药物的效果、减少对酒精的渴望、产生类似可卡因的快感，以及镇静或助眠。最有可能滥用加巴喷丁的人群包括滥用阿片类药物者、精神疾病患者或有先前处方药物滥用史者。各州目前正在通过处方监测计划采取行动来跟踪加巴喷丁的使用情况，有些州已将其重新归类为附表 V 受控物质。本述评总结了加巴喷丁的滥用潜力，介绍了各州针对加巴喷丁监测所采取的措施，并讨论了在开具加巴喷丁处方时可能产生的临床影响和增强患者安全的方法。
